Pfizer Inc. (PFE) Shares Bought by Access Financial Services Inc.
Access Financial Services Inc. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 14.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 44,259 shares of the biopharmaceutical company’s stock after buying an additional 5,672 shares during the quarter. Pfizer accounts for approximately 1.2% of Access Financial Services Inc.’s holdings, making the stock its 19th largest holding. Access Financial Services Inc.’s holdings in Pfizer were worth $1,580,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of PFE. Shine Investment Advisory Services Inc. bought a new position in Pfizer during the 2nd quarter worth about $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer during the 2nd quarter worth about $103,000. D. Scott Neal Inc. increased its holdings in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares in the last quarter. Herndon Capital Management LLC bought a new position in Pfizer during the 2nd quarter worth about $120,000. Finally, Private Vista LLC increased its holdings in Pfizer by 2,277.3% during the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 190,933 shares in the last quarter. 69.75% of the stock is currently owned by institutional investors and hedge funds.
In related news, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The disclosure for this sale can be found here. Insiders have sold 29,450 shares of company stock valued at $1,065,220 in the last quarter. 0.06% of the stock is currently owned by corporate insiders.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter last year, the company earned $0.61 EPS. Pfizer’s revenue for the quarter was up .9% compared to the same quarter last year. sell-side analysts expect that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
Pfizer declared that its board has approved a share repurchase program on Monday, December 18th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be issued a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.68%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.
A number of equities analysts have issued reports on PFE shares. Nord/LB reiterated a “neutral” rating on shares of Pfizer in a report on Wednesday, December 27th. Deutsche Bank set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Goldman Sachs Group set a $36.00 target price on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, November 1st. BMO Capital Markets set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a report on Friday, December 15th. Finally, Jefferies Group set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $38.94.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2018/01/19/pfizer-inc-pfe-shares-bought-by-access-financial-services-inc.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.